Masataka Adachi

Masataka Adachi

Auto-generated profile, based on publicly available information

Masataka Adachi

Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo 1608582, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2015 in Oncology Reports
Verified
Journal Article
Open access
PDF file
TTTakashi Takeda
Takashi Takeda
KBKouji Banno
Kouji Banno
RORyuichiro Okawa
Ryuichiro Okawa
MYMegumi Yanokura
Megumi Yanokura
MIMoito Iijima
Moito Iijima
DADaisuke Aoki
Daisuke Aoki
The AT-rich interacting domain‑containing protein 1A gene (ARID1A) encodes ARID1A, a member of the SWI/SNF chromatin remodeling complex. Mutation of ARID1A induces changes in expression of multiple genes (CDKN1A, SMAD3, MLH1 and PIK3IP1) via chromatin remodeling dysfunction, contributes to carcinogenesis, and has been shown to cause transformation of cells in association with the PI3K/AKT pathway. Information on ARID1A has emerged from comprehensive genome‑wide analyses with next‑generation sequencers. ARID1A mutations have been found in various types of cancer and occur at high frequency in endometriosis‑associated ovarian cancer, including clear cell adenocarcinoma and endometrioid adenocarcinoma, and also occur at endometrial cancer especially in endometrioid adenocarcinoma. It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis‑associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer. Therefore, development of a screening method that can detect mutations of ARID1A and activation of the PI3K/AKT pathway might enable early diagnosis of endometriosis‑associated ovarian cancers and endometrial cancers. Important results may also emerge from a current clinical trial examining a multidrug regimen of temsirolimus, a small molecule inhibitor of the PI3K/AKT pathway, for treatment of advanced ovarian clear cell adenocarcinoma with ARID1A mutation and PI3K/AKT pathway activation. Also administration of sorafenib, a multikinase inhibitor, can inhibit cancer proliferation with PIK3CA mutation and resistance to mTOR inhibitors and GSK126, a molecular‑targeted drug can inhibit proliferation of ARID1A‑mutated ovarian clear cell adenocarcinoma cells by targeting and inhibiting EZH2. Further studies are needed to determine the mechanism of chromatin remodeling dysregulation initiated by ARID1A mutation, to develop methods for early diagnosis, to investigate new cancer therapy targeting ARID1A, and to examine the involvement of ARID1A mutations in development, survival and progression of cancer cells.

20 August 2014 in Molecular and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
KNKanako Nakamura
Kanako Nakamura
KBKouji Banno
Kouji Banno
MYMegumi Yanokura
Megumi Yanokura
MIMiho Iida
Miho Iida
MAMasataka Adachi
Masataka Adachi
DADaisuke Aoki
Daisuke Aoki
Lynch syndrome is a hereditary ovarian cancer with a prevalence of 0.9‑2.7%. Lynch syndrome accounts for 10‑15% of hereditary ovarian cancers, while hereditary breast and ovarian cancer syndrome accounts for 65‑75% of these cancers. The lifetime risk for ovarian cancer in families with Lynch syndrome is ~8%, which is lower than colorectal and endometrial cancers, and ovarian cancer is not listed in the Amsterdam Criteria II. More than half of sporadic ovarian cancers are diagnosed in stage III or IV, but ≥80% of ovarian cancers in Lynch syndrome are diagnosed in stage I or II. Ovarian cancers in Lynch syndrome mostly have non‑serous histology and different properties from those of sporadic ovarian cancers. A screening method for ovarian cancers in Lynch syndrome has yet to be established and clinical studies of prophylactic administration of oral contraceptives are not available. However, molecular profiles at the genetic level indicate that ovarian cancer in Lynch syndrome has a more favorable prognosis than sporadic ovarian cancer. Inhibitors of the phosphatidylinositol 3‑kinase/mammalian target of the rapamycin pathway and anti‑epidermal growth factor antibodies may have efficacy for the disease. To the best of our knowledge, this is the first review focusing on ovarian cancer in Lynch syndrome.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
KBKouji Banno
Kouji Banno
MYMegumi Yanokura
Megumi Yanokura
MIMiho Iida
Miho Iida
MAMasataka Adachi
Masataka Adachi
KNKanako Nakamura
Kanako Nakamura
DADaisuke Aoki
Daisuke Aoki
Ovarian cancer has a poor prognosis because early detection is difficult and recurrent ovarian cancer is usually drug-resistant. The morbidity and mortality of ovarian cancer are high worldwide and new methods of diagnosis and therapy are needed. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression that are involved in carcinogenesis, metastasis, and invasion. Thus, miRNAs are likely to be useful as diagnostic and prognostic biomarkers and for cancer therapy. Many miRNAs have altered expression in ovarian cancer compared to normal ovarian tissues and these changes may be useful for diagnosis and treatment. For example, deficiencies of enzymes including Dicer and Drosha that are required for miRNA biogenesis may be adverse prognostic factors; miRNAs such as miR-214 and miR-31, which are involved in drug resistance, and the miR-200 family, which is implicated in metastasis, may serve as biomarkers; and transfection of downregulated miRNAs and inhibition of upregulated miRNAs may be effective for treatment of ovarian cancer. Chemotherapy targeting epigenetic mechanisms associated with miRNAs may also be effective to reverse gene silencing.

7 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
Yusuke KobayashiYusuke Kobayashi
Yusuke Kobayashi
HKHiroyasu Kashima
Hiroyasu Kashima
YRYohan Suryo Rahmanto
Yohan Suryo Rahmanto
KBKouji Banno
Kouji Banno
YYYu Yu
Yu Yu
DADaisuke Aoki
Daisuke Aoki
Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer

20 July 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
HKHaruko Kunitomi
Haruko Kunitomi
KBKouji Banno
Kouji Banno
MYMegumi Yanokura
Megumi Yanokura
TTTakashi Takeda
Takashi Takeda
MIMoito Iijima
Moito Iijima
DADaisuke Aoki
Daisuke Aoki
The increasing incidence of obesity and diabetes due to changes in diet, earlier menarche, delayed menopause, late marriage, and declining birth rate have resulted in an increase in the number of endometrial cancer cases over the last few decades. Although surgical therapy is sufficient for early endometrial cancer, there is no effective therapy for patients with advanced and recurrent endometrial cancer. The oncogenic mechanism of endometrial cancer involves microsatellite instability (MSI) caused by dysfunction of DNA mismatch repair genes in 30% of patients. Immune checkpoint inhibitors, including anti‑programmed death (PD)‑1 and anti‑PD‑ligand 1 antibodies, are of interest as novel anticancer drugs; however, these drugs are currently expensive, and there is a need to select patients who will benefit from their use. The use of MSI analysis as a predictive biomarker for the therapeutic efficacy of these drugs may be useful for reducing the costs of drug therapy.

22 January 2015 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
KUKiyoko Umene
Kiyoko Umene
MYMegumi Yanokura
Megumi Yanokura
KBKouji Banno
Kouji Banno
HIHaruko Irie
Haruko Irie
MAMasataka Adachi
Masataka Adachi
DADaisuke Aoki
Daisuke Aoki
Aurora kinase A (AURKA) regulates the cell cycle checkpoint and maintains genomic integrity. AURKA is overexpressed in various malignant tumors and its upregulation induces chromosomal instability, which leads to aneuploidy and cell transformation. To investigate the role of AURKA in endometrial cancer, we evaluated the association of immunohistochemical expression of AURKA with clinicopathological factors. Furthermore, we examined the effects of AURKA inhibition by transfected siRNA in HEC‑1B cells on colony‑forming ability, invasion and migration capacity, and chemosensitivity. Immunohistochemical staining showed that overexpression of AURKA was significantly associated with tumor grade (P<0.05) and poor histologic differentiation (P<0.05). The recurrence rate also tended to be high in cases with overexpression of AURKA (P<0.1) and these cases also had a tendency for shorter disease‑free survival (DFS) (P<0.1). AURKA inhibition in endometrial cancer cell lines significantly decreased cell growth, invasion and migration (P<0.05), and increased chemosensitivity to paclitaxel. We also evaluated the efficacy of a combination of AURKA siRNA and paclitaxel against subcutaneous tumors formed in a nude mouse. After treatment, the tumor volume shrank significantly compared to treatment with paclitaxel only (P<0.05). To our knowledge, this is the first study in endometrial carcinoma to show a correlation between overexpression of AURKA and tumor grade, histological type and sensitivity to paclitaxel. AURKA is a promising therapeutic target in endometrial cancer and the combination therapy with AURKA inhibitors and paclitaxel could be effective for endometrial cancer that is resistant to conventional treatment and has a poor prognosis.